European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

On November 16, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, reported that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches," said Dr. Thomas Seufferlein, medical director, Clinic for Internal Medicine I, Ulm University Hospital. "The European Commission’s approval of daraxonrasib represents an important advance for patients with this aggressive and difficult-to-treat disease. The unprecedented survival benefit demonstrated in the RASolute 302 clinical trial underscores the potential of daraxonrasib to establish a new standard of care for eligible patients with metastatic pancreatic cancer across the European Union."

"Today’s European Commission approval of RASONQUE represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "With RASONQUE now approved, we are actively working with healthcare systems and stakeholders across the region to support timely access for eligible patients. We also continue to engage with regulatory authorities around the world with the goal of expanding and accelerating the reach of RASONQUE to patients who may benefit from it."

The approval by the EC follows the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which was part of an expedited phased review under the EMA’s Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.

The EC approval is based on results from the Phase 3 RASolute 302 clinical trial, presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and simultaneously published in The New England Journal of Medicine. RASolute 302 was a global, randomized Phase 3 trial evaluating RASONQUE versus investigator’s choice of cytotoxic chemotherapy in patients with previously treated metastatic PDAC. The trial met all primary and key secondary endpoints in both the RAS G12 mutant population and the overall intent-to-treat (ITT) population, which included patients with or without an identified tumor RAS mutation.

The EC has granted marketing authorization for RASONQUE in all European Union member states as well as the European Economic Area (EEA) countries Iceland, Norway, and Liechtenstein. This marketing authorization does not apply in the United Kingdom or Switzerland, which have separate regulatory approval processes.

Revolution Medicines is working closely with reimbursement and assessment bodies in European Union countries to enable broad and rapid access to patients in need. Timing of patient access will vary by country and depends on completion of national pricing, health-technology assessment and reimbursement processes.

About Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and among the most lethal malignancies, frequently with a late diagnosis, aggressive biology, and limited responsiveness to conventional treatments. RAS, a key growth control switch in human cells, is the main driver of pancreatic cancer, which is characterized by excessive RAS signaling. Approximately 147,000 people are diagnosed with pancreatic cancer in Europe each year, and the five-year survival rate remains below 10%.2,3 Because early-stage pancreatic cancer often causes few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread, when treatment options are more limited.4

About RASONQUETM (daraxonrasib)

RASONQUE (daraxonrasib) is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor (TCI), approved by the U.S. FDA for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy, and granted marketing authorization by the EC for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1,5 RASONQUE is being investigated through global Phase 3 registrational trials in patients with PDAC and metastatic RAS mutant non-small cell lung cancer (NSCLC).

About the RASolute 302 Clinical Trial

RASolute 302 (NCT06625320) was a global, randomized Phase 3 registrational clinical trial designed to evaluate the efficacy and safety of RASONQUE as a monotherapy in patients with previously treated metastatic pancreatic adenocarcinoma (PDAC). In the trial, patients were randomized to receive either an oral dose of 300 mg RASONQUE once daily or investigator’s choice of four different cytotoxic chemotherapy regimens, which represented standard of care across the globe. The trial enrolled patients with metastatic PDAC harboring a wide range of RAS variants, including those with RAS G12 mutations (such as G12D, G12V, and G12R), as well as patients without an identified tumor RAS mutation (wild-type).

The primary endpoints of the RASolute 302 trial were progression-free survival (PFS), as assessed by a Blinded Independent Central Review according to RECIST 1.1, and overall survival (OS) in patients with tumors harboring RAS G12 mutations. Secondary endpoints included PFS and OS in all enrolled patients (the intent-to-treat population) encompassing patients with and without identified tumor RAS mutations, as well as objective response rate, duration of response, and patient-reported quality of life.

EU Indication

RASONQUE as monotherapy is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

U.S. INDICATION

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

U.S. IMPORTANT SAFETY INFORMATION

RASONQUE is associated with the following Warnings and Precautions: Dermatologic and Soft Tissue Toxicity, Stomatitis and Oral Disorders, Diarrhea, Gastrointestinal Perforation, Interstitial Lung Disease (ILD)/Pneumonitis, and Embryo-Fetal Toxicity.

U.S. WARNINGS AND PRECAUTIONS

Dermatologic and Soft Tissue Toxicity

RASONQUE can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures. In clinical trials of patients with pancreatic adenocarcinoma, dermatologic toxicity occurred in 86% of patients treated with RASONQUE, of which 10% were Grade 3.

Monitor patients who develop dermatologic or soft tissue toxicities while receiving RASONQUE. Initiate prophylactic measures (e.g., topical corticosteroids, emollient creams, sunscreen, oral antibiotics) prior to the first dose of RASONQUE to reduce the risk of moderate to severe dermatologic reactions. Advise patients to limit sun exposure while taking RASONQUE. Initiate supportive measures (e.g., oral corticosteroids) as clinically indicated, and consider dermatologic consultation. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Stomatitis and Oral Disorders

RASONQUE can cause stomatitis, including mouth ulcers and oral mucositis. In clinical trials of patients with pancreatic adenocarcinoma, stomatitis occurred in 57% of patients, of which 9% were Grade 3.

Monitor patients for signs and symptoms of stomatitis while receiving RASONQUE. Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Diarrhea

RASONQUE can cause diarrhea. In clinical trials of patients with pancreatic adenocarcinoma, diarrhea occurred in 63% of patients, of which 6% were Grade 3.

If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Gastrointestinal Perforation

RASONQUE can cause gastrointestinal perforation. In clinical trials of patients with pancreatic adenocarcinoma, gastrointestinal perforation occurred in 0.9% of patients treated with RASONQUE, of which 0.5% were Grade 3, one event was Grade 4, and one event was fatal.

Monitor patients for gastrointestinal perforation. Withhold RASONQUE if gastrointestinal perforation is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of gastrointestinal perforation are identified.

Interstitial Lung Disease (ILD)/Pneumonitis

RASONQUE can cause interstitial lung disease or pneumonitis. In clinical trials of patients with pancreatic adenocarcinoma, ILD/pneumonitis occurred in 2.4% of patients treated with RASONQUE, of which 0.9% were Grade 3, and one event was fatal.

Monitor patients for new or worsening pulmonary symptoms. Withhold RASONQUE if ILD/pneumonitis is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of ILD/pneumonitis are identified.

Embryo-Fetal Toxicity

Based on findings in animals, RASONQUE can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).

Adverse reactions leading to permanent discontinuation of RASONQUE occurred in 2.9% of patients, including two patients who discontinued due to rash (0.8%).

The most common (≥ 20%) adverse reactions in patients treated with RASONQUE were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

DRUG INTERACTIONS

Strong CYP3A Inhibitors with P-gp Inhibition: Avoid concomitant use.
Strong CYP3A Inhibitors without P-gp Inhibition: Reduce RASONQUE dosage.
Moderate CYP3A Inhibitors with or without P-gp Inhibition: Reduce RASONQUE dosage.
P-gp Inhibitors: Reduce RASONQUE dosage.
Cyclosporine A: Avoid concomitant use.
Strong CYP3A Inducers: Avoid concomitant use. Increase RASONQUE dosage if concomitant use cannot be avoided.
Moderate CYP3A Inducers: Increase RASONQUE dosage.
P-gp Substrates: Take at least 4 hours apart from RASONQUE.


PROPHYLACTIC MEASURES

When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications are recommended to reduce the risk of dermatologic reactions:

administer a topical corticosteroid (applied to the face and chest) and emollient creams
advise patients to limit sun exposure and use broad-spectrum sunscreen (SPF 30 or higher)
consider prophylactic oral antibiotics (e.g., doxycycline or minocycline)

Please see U.S. Full Prescribing Information for RASONQUE.

(Press release, Revolution Medicines, NOV 16, 2026, View Source [SID1234674814])

Rakuten Medical Initiates First-in-Human Phase 1 Trial of PD-L1-Targeted RM-0256 Photoimmunotherapy in Japan

On November 16, 2026 Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox platform-based photoimmunotherapy, reported that it has initiated a Phase 1 clinical trial of RM-0256 photoimmunotherapy in Japan. RM-0256, an anti-PD-L1 antibody-light-activatable dye conjugate, is the third drug candidate developed by Rakuten Medical based on its Alluminox platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study (RM-0256-101 / jRCT2031260118) is a first-in-human, open-label, non-controlled, dose-escalation trial that will enroll 24 patients with solid tumors, including malignant skin tumors, who are refractory to or ineligible for standard treatment. It is being conducted at Kobe University Hospital (Principal Investigator: Naomi Kiyota, M.D., Ph.D.), National Cancer Center Hospital (Principal Investigator: Noboru Yamamoto, M.D., Ph.D.), and National Cancer Center Hospital East (Principal Investigator: Akira Takahashi, M.D., Ph.D.).

The study is being funded by the Japan Agency for Medical Research and Development (AMED) to support the development of RM-0256 for advanced or recurrent malignant epithelial skin tumors, which are the initial target indication in this study.

The primary objectives of the study are to evaluate the safety and tolerability of RM-0256 photoimmunotherapy and to identify recommended drug and light doses for Phase 2 clinical development. Primary endpoints includes dose-limiting toxicities and adverse events. Secondary endpoints includes tumor response and pharmacokinetic parameters of RM-0256. Exploratory assessments will also evaluate biomarkers associated with RM-0256 photoimmunotherapy.

Background on PD-L1 and RM-0256
PD-L1 is an immune checkpoint protein expressed on tumor cells and on immunosuppressive cells in the tumor microenvironment, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). The interaction of PD-L1 with PD-1 on activated T cells may suppress T-cell-mediated antitumor immune responses.

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have become standard treatments for a variety of cancer types. However, there remains a need for novel treatment options for patients with highly immunosuppressed tumors or tumors that are resistant to ICIs.

RM-0256 is an antibody-dye conjugate comprising AB-256, a proprietary anti-PD-L1 monoclonal antibody developed by Rakuten Medical, and IRDye 700DX (IR700), a light-activatable dye. RM-0256 specifically binds to cells expressing PD-L1. In RM-0256 photoimmunotherapy, RM-0256 is administered intravenously, followed approximately 24 hours later by illumination of the targeted lesion with 690 nm laser light. The laser light transiently activates IR700, which, in preclinical studies, has been shown to induce necrosis or elimination of RM-0256-bound target cells.

Preclinical studies have suggested that RM-0256 photoimmunotherapy may act through three complementary mechanisms:

Elimination of PD-L1–expressing immunosuppressive cells;
Direct destruction of PD-L1-expressing tumor cells; and
Immune checkpoint blockade through inhibition of PD-L1/PD-1 interaction, potentially enhancing systemic antitumor immune responses.
About Alluminox platform
The Alluminox platform is Rakuten Medical’s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical’s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical’s Alluminox platform-based photoimmunotherapy is investigational.

(Press release, Rakuten Medical, NOV 16, 2026, View Source [SID1234674831])

Olema Oncology to Participate in Upcoming Investor Conferences

On November 17, 2026 Olema Oncology, Inc. ("Olema," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that the Company will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

9th Annual Evercore Healthcare Conference
Date and Time: November 30, 2026 at 2:35 p.m. ET
Format: Fireside Chat
Location: Miami, FL

Citi’s 2026 Global Healthcare Conference
Date and Time: December 1, 2026 at 1:00 p.m. ET
Format: Fireside Chat
Location: Miami, FL

Piper Sandler 38th Annual Healthcare Conference
Date and Time: December 2, 2026 at 1:30 p.m. ET
Format: Fireside Chat
Location: New York, NY

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

(Press release, Olema Oncology, NOV 16, 2026, View Source [SID1234674847])

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

On November 16, 2026 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, reported financial results and provided operational updates for the quarter ended September 30, 2026, and a rinzimetostat program update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC," said Jacob M. Chacko, M.D., president and chief executive officer. "With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer."

Third Quarter 2026 and Other Recent Highlights

Rinzimetostat: a potent and selective allosteric inhibitor of PRC2

Second Half 2026 Program Update

The Company conducted a pre-planned biannual Periodic Safety Review (PSR) in October 2026 for the ongoing Phase 1b dose-optimization cohorts evaluating 400 mg QD rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and in patients with mCRPC previously treated with an androgen receptor (AR) inhibitor. As of August 14, 2026, with a median follow-up of approximately 8 months, the safety profile across both patient populations was consistent with the prior March 2026 data disclosure; the vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity and consistent with PRC2 and AR inhibition. The most common TRAEs were fatigue (32%; 11% Grade 1, 16% Grade 2, and 5% Grade 3), diarrhea (24%; 19% Grade 1 and 5% Grade 2), and nausea (22%; 19% Grade 1 and 3% Grade 2), which are similar rates and grades to the March 2026 disclosure. Consistent with the prior disclosure, there were no Grade 4 or 5 adverse events attributed to rinzimetostat or darolutamide. These data continue to demonstrate a highly differentiated safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and fewer treatment modifications than competitor regimens.

In parallel with the PSR, longer-term durability was also evaluated across both patient populations.

Post-abiraterone cohort: At the time of the previous data disclosure (March 6, 2026 data cutoff), of 18 efficacy-evaluable patients in this cohort, 7 remained on treatment without radiographic progression. As of the August 14, 2026 data cutoff, 2 of these 7 patients discontinued treatment due to radiographic progression (one at more than 13 months and one at more than 11 months), and 5 patients remained on treatment without radiographic progression, with the longest ongoing at nearly 17 months. While still preliminary with 28% of patients ongoing, landmark rPFS rates continue to demonstrate meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. With a median follow-up of 7.8 months, landmark rPFS rates of 59% at each of 8, 9, and 10 months are consistent with the competitor PRC2 inhibitor currently in multiple Phase 3 trials in prostate cancer (mevrometostat in combination with enzalutamide demonstrated estimated landmark rPFS rates of 63% at each of 8, 9, and 10 months in a post-abiraterone patient population). These rinzimetostat landmark rPFS rates are superior to reported outcomes for available standard-of-care therapies, including Xtandi, Jevtana, Taxotere, and Pluvicto. For reference, the estimated 10-month landmark rPFS for these approved therapies ranges from approximately 35% to 50%.
Post-AR inhibitor cohort: At the time of the previous data disclosure (March 6, 2026 data cutoff), of 19 efficacy-evaluable patients in this cohort, 8 remained on treatment without radiographic progression. As of the August 14, 2026 data cutoff, 2 of these 8 patients discontinued treatment (one at nearly 10 months due to clinical progression; one at more than 8 months due to an adverse event), and 6 patients remained on treatment without radiographic progression, 4 of whom are ongoing at between 12 to 16 months. While still preliminary with 32% of patients ongoing, landmark rPFS rates continue to demonstrate meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. With a median follow-up of 7.6 months, landmark rPFS rates of 71%, 59%, and 59% at 8, 9, and 10 months, respectively, are consistent with the competitor PRC2 inhibitor currently in multiple Phase 3 trials in prostate cancer (mevrometostat in combination with enzalutamide demonstrated estimated landmark rPFS rates of 58%, 54%, and 54% at 8, 9 and 10 months, respectively, in a post-AR inhibitor patient population). These rinzimetostat landmark rPFS rates are superior to reported outcomes for available standard-of-care therapies, including Zytiga, Jevtana, Taxotere, and Pluvicto. For reference, the estimated 10-month landmark rPFS for these approved therapies ranges from approximately 15% to 50%.

Additional Rinzimetostat Third Quarter 2026 and Other Recent Highlights

Finalized the trial protocol and initiated the Himalayas-1 global Phase 3 registrational trial following End-of-Phase 1 interactions with the FDA and other global health authorities. The Himalayas-1 trial is expected to enroll approximately 600 patients from over 250 sites in 25 countries, randomized 1:1 to receive 400 mg once daily oral rinzimetostat (with or without food) in combination with darolutamide versus physician’s choice of an AR inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival and the key secondary endpoint is overall survival.
Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1. Under the terms of the agreement, ORIC will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor, NUBEQA (darolutamide), at no cost for use in the trial in combination with rinzimetostat. This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.
Presented preclinical data at ESMO (Free ESMO Whitepaper) Congress 2026 highlighting potential advantages of targeting PRC2 via EED over EZH2, including that prostate cancer cells that rapidly developed resistance to the EZH2 inhibitor mevrometostat acquired an EZH2 mutation against which the potency of the EED inhibitor rinzimetostat was maintained. Preclinical results, supported by translational data in mCRPC patient samples, showed rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition.

Enozertinib: a brain-penetrant, selective inhibitor targeting EGFR atypical mutations and EGFR exon 20 insertion mutations

Presented potential best-in-class Phase 1b data at ESMO (Free ESMO Whitepaper) Congress 2026 in 1L NSCLC patients with EGFR atypical mutations. Despite enrolling patients with more than double the rate of baseline CNS disease as competitor datasets, including previously untreated CNS metastases, enozertinib demonstrated:
Meaningful systemic and compelling CNS responses: 84% confirmed systemic and 70% confirmed intracranial ORRs by investigator. These findings were supported by similar response rates utilizing the more stringent blinded independent central review (BICR), with a systemic ORR of 80% (RECIST 1.1) and an intracranial ORR of 67% (RANO-BM).
Promising early durability: while median PFS and duration of response data were immature as of the October 2026 data presentation cutoff date, a majority of patients remained on treatment and the 6-month landmark PFS of 88% compares favorably to reported benchmarks for currently used therapies and for late-stage investigational therapies.
A well-tolerated safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in no treatment-related discontinuations.
Supported by potential best-in-class data and based on End-of-Phase 1 interactions with the FDA, ORIC announced plans to initiate Redwood-1, a global Phase 3 registrational trial in 1L EGFR atypical NSCLC in 1H 2027. The Redwood-1 trial is expected to enroll approximately 360 patients with EGFR PACC and L861X mutations, including those with untreated brain metastases, randomized to receive 80 mg once daily oral enozertinib or physician’s choice of osimertinib or afatinib. Dual primary endpoints include ORR by BICR for potential accelerated approval as well as PFS by BICR for full approval. Key secondary endpoints include overall survival and intracranial ORR by BICR RANO-BM.

ORIC-259: a potent, selective, oral small molecule degrader of CIP2A mRNA

Announced agreement with Cancer Research UK (CRUK) to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy into clinical development. Under the agreement, CRUK will fully fund, sponsor, design, and execute CTA-enabling activities and early clinical development of ORIC-259 for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with CRUK eligible to receive downstream milestone payments and royalties.

Key Achievements and Anticipated Program Milestones:

Rinzimetostat in mCRPC:
Announced combination dose optimization data with AR inhibitor
Initiated first global Phase 3 registrational trial in post-abiraterone mCRPC
2H 2026: Program update
Enozertinib in NSCLC:
October 2026: 1L EGFR atypical monotherapy data presented at ESMO (Free ESMO Whitepaper) Congress 2026
1H 2027: Initiate first global Phase 3 registrational trial in 1L EGFR atypical
Mid-2027: 1L EGFR exon 20 monotherapy data and combination data with SC amivantamab and combination with chemotherapy

Third Quarter 2026 Financial Results

Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $345.4 million as of September 30, 2026, which includes $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under the ATM (at-the-market) program. The company expects its cash and investments to fund the operating plan into 2H 2028.
R&D Expenses: Research and development (R&D) expenses were $43.4 million for the three months ended September 30, 2026, compared to $28.8 million for the three months ended September 30, 2025, an increase of $14.6 million. The increase was primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs. For the nine months ended September 30, 2026, R&D expenses were $111.1 million, compared to $84.0 million for the nine months ended September 30, 2025, an increase of $27.1 million. The increase was primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs as well as lower preclinical costs.
G&A Expenses: General and administrative (G&A) expenses were $8.2 million for the three months ended September 30, 2026, compared to $7.9 million for the three months ended September 30, 2025, an increase of $0.3 million. For the nine months ended September 30, 2026, G&A expenses were $25.4 million, compared to $24.5 million for the nine months ended September 30, 2025, an increase of $0.9 million. The increases were primarily due to higher professional services costs.

(Press release, ORIC Pharmaceuticals, NOV 16, 2026, View Source [SID1234674815])

Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis

On November 16, 2026 Calytrix Bio, Inc. ("Calytrix"), a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs), reported a definitive agreement for Eli Lilly and Company ("Lilly") to acquire Calytrix.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Calytrix’s lead asset is an investigational biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). It is designed to deliver disease-modifying pan-mutant activity, with a safety and convenience profile that supports early intervention and long-term treatment. Current drug therapies for ET and MF primarily manage symptoms and complications, creating an opportunity for precision therapies that target the disease driver mutations. Mutant CALR provides a tumor-specific cell-surface target with the potential to deplete the disease-driving mutant clone while sparing normal tissues and preserving healthy hematopoiesis.

"Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, President and Chief Executive Officer of Calytrix Bio. "From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s program to the starting line for clinical development."

Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm within J.P. Morgan Asset Management. The company launched with a Series A financing co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners, followed by a Series B financing led by Avoro Ventures.

For Calytrix, Centerview Partners LLC is acting as exclusive financial advisor, and Goodwin Procter LLP is acting as legal counsel. For Lilly, Paul, Weiss, Rifkind, Wharton & Garrison LLP is acting as legal counsel.

(Press release, Eli Lilly, NOV 16, 2026, View Source [SID1234674832])